Drug Policy Watch · State Brief 2026

Rhode Island

Snapshot (structured)

Adult-use cannabis: Legal since 2022 (Rhode Island Cannabis Act). Retail sales live; the 51 percent residency requirement was repealed in June 2026 (H 8544 / S 3313) and licensing is restarting, though the market stays capped at 24 retailers.
Medical cannabis: Legal and long-established; administered through the Cannabis Control Commission.
Home grow: Yes. Medical patients up to 12 mature plus 12 immature plants; adult-use limited home grow permitted with plant tags.
Intoxicating hemp / hemp THC: Restricted. Hemp consumables capped at 1 mg total THC per serving and 5 mg per package; regulators back pushing hemp THC beverages into the licensed cannabis system.
Psychedelics: Not yet legal. Recurring Potter/Kallman psilocybin decriminalization bill, passed the House in prior sessions; 2026 exact bill number unconfirmed.
Broad decriminalization: Cannabis decriminalized/legalized; no broad all-drug decriminalization. Fentanyl test strips decriminalized since 2018.
Harm reduction: Strong. Syringe services, naloxone, fentanyl test strips, and the nation's first state-sanctioned overdose prevention center.
Governor (party): Daniel J. McKee (Democrat).
Legislature control: Democratic trifecta. Senate roughly 34 D to 4 R; House roughly 64 D, 10 R, 1 Independent (post-2024 election).
Citizen ballot initiatives allowed: No. Rhode Island has no statewide citizen initiative process.
Enclosure pressure score: 3/5

Cannabis

Rhode Island legalized adult-use cannabis in May 2022 when Governor McKee signed the Rhode Island Cannabis Act (S 2430 / H 7593). The Act created a comprehensive regulatory and tax structure and folded the pre-existing medical program into the same regime. Source: https://governor.ri.gov/press-releases/governor-mckee-signs-legislation-legalizing-and-safely-regulating-recreational and https://www.mpp.org/states/rhode-island/summary-of-the-rhode-island-cannabis-act-(s-2430/h-7593)/

Medical cannabis remains legal and well-established. Registered patients can grow up to 12 mature and 12 immature plants at home and may purchase up to 2.5 ounces within a 15-day period. Source: https://rhodeislandcannabis.org/laws

Market structure. The Cannabis Control Commission (CCC) is an independent regulator; its rules (RICR Title 560) became final and effective May 1, 2025. Source: https://cannabispromotions.com/regulations/states/rhode-island and https://ccc.ri.gov/. The Cannabis Act caps the adult-use market at 24 retail establishments statewide, divided across six geographic zones with a maximum of 4 per zone. The original cohort came largely from converted medical compassion centers, leaving roughly 7 operating retailers in 2025 that produced about $120 million in sales, roughly $15 million per store, reported as among the highest per-store revenue in the nation. Source: https://www.cannabisbusinesstimes.com/us-states/rhode-island/news/15755345/rhode-island-opens-applications-for-24-adultuse-dispensary-licenses

License caps and new licenses. The CCC opened applications for the remaining 24 license slots: structured as 12 open, 6 social equity, and 6 worker cooperative licenses (reporting varies on whether about 20 net-new licenses were on offer given existing operators). Complete applications were due December 29, 2025, with a March 2, 2026 deadline for final zoning approval documentation, and a lottery tentatively set for May 2026. Source: https://www.cann.dev/rhode-island-cannabis-retail-licensing-2026/ and https://www.cannabisbusinesstimes.com/us-states/rhode-island/news/15755345/rhode-island-opens-applications-for-24-adultuse-dispensary-licenses

The residency requirement, injunction, and June 2026 repeal (the central 2026 cannabis story). Rhode Island's law required that a majority (51 percent) of a retail cannabis company be owned by a Rhode Island resident, while otherwise allowing out-of-state investment. Out-of-state entrepreneurs (Justyna Jensen of California and John Kenney of Florida in May 2024, and Justin Palmore of California in November 2025) sued in U.S. District Court, arguing the requirement violates the dormant Commerce Clause. On April 8, 2026, U.S. District Judge Melissa DuBose issued a preliminary injunction finding the residency requirement was not narrowly tailored, blocking the CCC from running the lottery or reviewing applications, and nearly 100 applicants were left in limbo. The General Assembly then resolved the dispute legislatively: in June 2026 Governor McKee signed H 8544 / S 3313, repealing the 51 percent residency requirement, voiding the prior application rounds, refunding applicant fees, and directing the CCC to restart licensing within about 60 days. That mooted the injunction, and the state moved to lift it in late June 2026. Source: https://rhodeislandcurrent.com/2026/04/10/cannabis-license-rollout-halted-as-federal-judge-blocks-enforcement-of-ris-residency-requirement/ and https://www.marijuanamoment.net/rhode-island-marijuana-business-license-lottery-blocked-by-federal-judge-amid-challenge-to-residency-rules/

After a closed-door meeting, the CCC had appealed to the U.S. 1st Circuit Court of Appeals in Boston, but the June 2026 repeal of the residency requirement (H 8544 / S 3313) mooted that appeal. Source: https://rhodeislandcurrent.com/2026/04/14/cannabis-control-commission-appeals-ruling-halting-license-rollout-after-closed-door-meeting/ and https://www.marijuanamoment.net/rhode-island-marijuana-officials-appeal-federal-court-ruling-blocking-licensing-lottery/

Key 2026 actions: the residency-requirement repeal (H 8544 / S 3313) and the restart of licensing described above; the THC beverage / hemp report and recommendations (see Hemp); and a leadership transition at the CCC (see Political landscape).

Hemp

Rhode Island treats intoxicating hemp restrictively. Hemp consumables are limited to 1 mg total THC per serving and 5 mg total THC per package. Source: https://www.cannabisregulations.ai/state-legality/rhode-island-thca

In the 2025 session, H 6270 sought to move hemp-derived delta-9 THC beverages and drink-mix powders out of convenience stores, liquor shops, and general retail and into licensed cannabis businesses only. Source: https://www.cannabisregulations.ai/cannabis-and-hemp-regulations-compliance-ai-blog/rhode-island-2025-hemp-thc-beverages-h6270. The state paused new hemp retailer licenses while studying intoxicating hemp; the General Assembly directed the Commission to deliver dosage, packaging, labeling, and licensing recommendations by March 1, 2026, and in March 2026 regulators backed banning THC drinks in bars and restaurants outside the licensed cannabis channel. Source: https://rhodeislandcurrent.com/2026/03/17/cannabis-regulators-back-ban-on-thc-drinks-in-ri-bars-and-restaurants/

Federal exposure and the November 12, 2026 deadline. The 2026 federal Farm Bill (passed the U.S. House) redefines hemp as cannabis testing no higher than 0.3% total THC including THCA, rather than the 2018 delta-9-only threshold, which would make an estimated 95 percent of existing hemp-derived THC products federally illegal as of November 12, 2026. Industry groups including the U.S. Hemp Roundtable are seeking a two-year delay (the Hemp Planting Predictability Act would push the date to November 2028); the bipartisan HEMP Act (H.7212, a federal bill) would set a federal regulatory framework instead. Source: https://www.cannabisbusinesstimes.com/hemp/news/15823852/s-house-passes-2026-farm-bill-intoxicating-hemp-product-ban-remains and https://vicentellp.com/insights/2026-federal-hemp-ban-what-it-means-for-the-future-of-consumable-hemp-products/. A Rhode Island Current op-ed in February 2026 argued for regulation over prohibition. Source: https://rhodeislandcurrent.com/2026/02/02/regulation-not-prohibition-congress-must-give-hemp-science-time-to-work/. Because Rhode Island already routes hemp intoxicants toward the licensed cannabis system, the federal change reinforces the state's existing direction more than it disrupts it, though it threatens the off-channel beverage and convenience-store market.

Psychedelics

Psilocybin is not legal in Rhode Island. Representative Brandon Potter (D) and Senator Meghan Kallman (D) have repeatedly sponsored a psilocybin decriminalization bill (historically numbered H 7047 in earlier sessions) that would exempt possession of up to one ounce of psilocybin cultivated for personal use, or shared person-to-person, from controlled-substances penalties, with a sunset (referenced as July 1, 2026 in earlier text) and a contingency that if the FDA reschedules psilocybin, the Rhode Island Department of Health would write rules for cultivation, distribution, and medical prescription. The bill stops short of a commercial retail system until federal change occurs. Source: https://www.marijuanamoment.net/rhode-island-bill-would-temporarily-legalize-psilocybin-use-home-cultivation-and-sharing/ and https://hightimes.com/news/rhode-island-bill-would-allow-psilocybin-cultivation-possession-under-1-ounce/

In prior sessions the House passed a Potter psilocybin bill and the House Judiciary Committee advanced a version 12-2 with amendments, while the Senate companion (Kallman) received a committee hearing. Source: https://www.marijuanamoment.net/rhode-island-house-panel-weighs-bill-that-would-temporarily-legalize-psilocybin/ and https://www.wpri.com/news/politics/ri-house-oks-bill-to-legalize-magic-mushrooms-statewide/. 2026 bills: the exact 2026 bill numbers and final 2026 status are unconfirmed; the recurring Potter (House) and Kallman (Senate) sponsorship is confirmed, but I could not confirm a 2026 enactment. Use the live tracker (below) to confirm current bill numbers and status.

Broader drug policy

Decriminalization. Cannabis is legalized; fentanyl test strips were decriminalized in 2018 (Rhode Island was the first state to do so), removing them from paraphernalia law. Source: https://www.networkforphl.org/news-insights/removing-legal-barriers-to-drug-testing-can-help-reduce-drug-related-harm/ and https://preventoverdoseri.org/fentanyl-test-strips/. There is no broad all-drug decriminalization on the Oregon model.

Harm reduction. The state offers free syringe/needle exchange, naloxone (Narcan), and fentanyl test strips. Source: http://weberrenew.org/harm-reduction/. Rhode Island opened the nation's first state-sanctioned overdose prevention center (supervised consumption site) in Providence, run by the nonprofit Project Weber/RENEW with clinical partner VICTA, at 45 Willard Avenue, with a ribbon-cutting in December 2024 and operations beginning that month. Operations are funded by opioid settlement dollars and the site is regulated by the Rhode Island Department of Health. The authorizing pilot law was set to sunset in March 2026, making reauthorization a key 2026 watch item. Source: https://thepublicsradio.org/health/rhode-island-opens-first-state-sanctioned-overdose-prevention-center-in-the-nation/ and https://weberrenew.org/overdose-prevention-center/ and https://weberrenew.org/a-year-of-saving-lives-at-the-nations-first-state-sanctioned-overdose-prevention-center/

Sentencing and expungement. The Cannabis Act created automatic expungement for prior cannabis possession convictions, with a process targeting completion by July 1, 2024; the Rhode Island Judiciary reported more than 23,000 cannabis possession convictions expunged by 2023. Source: https://www.gmlaw.com/news/rhode-island-cannabis-act-legalizes-adult-use-in-the-ocean-state/ and https://www.mpp.org/states/rhode-island/summary-of-the-rhode-island-cannabis-act-(s-2430/h-7593)/

Political landscape

Governor: Daniel J. McKee (Democrat), in office since 2021, running for re-election in 2026. Source: https://ballotpedia.org/Governor_of_Rhode_Island and https://en.wikipedia.org/wiki/2026_Rhode_Island_gubernatorial_election

Legislature: Democratic trifecta. After the 2024 elections the Senate was approximately 34 Democrats to 4 Republicans (38 seats) and the House approximately 64 Democrats, 10 Republicans, and 1 Independent (75 seats). Source: https://en.wikipedia.org/wiki/Rhode_Island_Senate and https://en.wikipedia.org/wiki/Rhode_Island_House_of_Representatives and https://ballotpedia.org/2025_Rhode_Island_legislative_session

Cannabis Control Commission leadership: founding chair Kim Ahern stepped down in October (2025) to run for attorney general. In May 2026, Governor McKee nominated Michelle Reddish, the state's top cannabis administrator, to chair the commission. Source: https://www.bostonglobe.com/2026/05/27/metro/ri-cannabis-control-commission-michelle-reddish/ and https://hempgazette.com/news/rhode-island-cannabis-control-commission-chair-nomination/ and https://www.newsfromthestates.com/article/ri-senate-confirms-new-cannabis-control-commission-chair

Reform champions: Rep. Brandon Potter (D) and Sen. Meghan Kallman (D) are the named psilocybin reform sponsors. Source: https://upriseri.com/representative-potter-senator-kallman-introduce-bill-to-decriminalize-magic-mushrooms/. Named opponents: I could not confirm specific named legislative opponents to current reform; opposition to the cannabis residency rule comes from out-of-state plaintiffs (Jensen, Kenney, Palmore) via litigation rather than from named legislators. Treat any other named opponents as unconfirmed.

Ballot initiatives

Rhode Island does not have a statewide citizen-initiated ballot measure process. Efforts to create one (a 1986 constitutional convention amendment, a 1996 advisory question that passed 53-47) did not result in adoption. Constitutional amendments and bond questions still reach the ballot, but only when referred by the legislature, not by citizen petition. There are no pending citizen-initiated drug-policy measures. Source: https://ballotpedia.org/History_of_direct_democracy_in_Rhode_Island and https://mapresearch.org/democracy-map/direct-citizen-initiative-states/

Equity and expungement

Social-equity licensing: the Cannabis Act reserves a dedicated tier of retail licenses for social equity applicants (6 of the 24 statewide, alongside 6 worker cooperative licenses). Qualifying criteria include at least 51 percent ownership by people who lived in a disproportionately impacted area for 5 of the past 10 years, by people with cannabis arrests/convictions eligible for expungement, or by people with income at or below 400 percent of the median in a disproportionately impacted area. The Act created a Social Equity Assistance Fund financed by $30,000 initial licensing fees and $125,000 medical-dispensary conversion fees. Source: https://www.mpp.org/states/rhode-island/summary-of-the-rhode-island-cannabis-act-(s-2430/h-7593)/ and https://quantum9.net/rhode-island-social-equity-cannabis-guide/

Expungement: automatic expungement of prior cannabis possession convictions, with more than 23,000 expunged as reported by 2023. Source: https://www.gmlaw.com/news/rhode-island-cannabis-act-legalizes-adult-use-in-the-ocean-state/

Who is excluded: the residency requirement was designed in part to keep local and equity owners in control, but it was repealed in June 2026 (H 8544 / S 3313), which voided the prior application rounds and directed the CCC to restart licensing within about 60 days. The new-license cohort, including the 6 equity and 6 worker-cooperative slots, must now reapply under the restarted process, and the market stays capped at 24 retailers.

Market and barriers

Taxes: roughly 20 percent total on adult-use cannabis, composed of a 10 percent state cannabis excise tax, a 3 percent local sales tax, plus the 7 percent state sales tax. Source: https://tax.ri.gov/tax-sections/sales-excise-taxes/adult-use-cannabis-tax and https://www.gmlaw.com/news/rhode-island-cannabis-act-legalizes-adult-use-in-the-ocean-state/

Fees and capital: initial cannabis license fee reported at $30,000; medical compassion center conversion fee at $125,000. Source: https://www.mpp.org/states/rhode-island/summary-of-the-rhode-island-cannabis-act-(s-2430/h-7593)/

Residency: the 51 percent Rhode Island resident ownership requirement for retail was repealed in June 2026 (H 8544 / S 3313); it had been blocked by a federal preliminary injunction before the repeal mooted the case. Source: https://rhodeislandcurrent.com/2026/04/10/cannabis-license-rollout-halted-as-federal-judge-blocks-enforcement-of-ris-residency-requirement/

License cap: 24 adult-use retail establishments statewide, 6 zones, max 4 per zone. Source: https://www.cannabisbusinesstimes.com/us-states/rhode-island/news/15755345/rhode-island-opens-applications-for-24-adultuse-dispensary-licenses

Approximate licensees: about 7 operating adult-use retailers in 2025; nearly 100 applicants competed for the remaining slots before the freeze. Source: https://www.cannabisbusinesstimes.com/us-states/rhode-island/news/15755345/rhode-island-opens-applications-for-24-adultuse-dispensary-licenses and https://rhodeislandcurrent.com/2026/04/10/cannabis-license-rollout-halted-as-federal-judge-blocks-enforcement-of-ris-residency-requirement/

Enclosure read

Rhode Island is partly fenced and, as of mid-2026, partly reopening. The market is hard-capped at 24 retailers, and the incumbents are a small set of converted medical operators earning the highest per-store revenue in the country. The expansion meant to open access (including dedicated equity and worker-cooperative tiers) was frozen for months by federal litigation over the residency rule, until the General Assembly repealed the 51 percent residency requirement in June 2026 (H 8544 / S 3313), voided the prior application rounds, refunded fees, and directed the CCC to restart licensing within about 60 days. That repeal lifted the licensing freeze that had sealed the capped market to new entrants, and the CCC is restarting licensing, so the state has moved from heavily enclosed toward partly open. Because the market stays capped at 24 retailers, the near-term effect still favors the entrenched incumbents and the larger, better-capitalized applicants (including out-of-state capital) best positioned to win the restarted, capped slots. Hemp is being funneled into the same licensed channel, fencing out convenience stores and independent beverage sellers, a pressure the federal November 12, 2026 hemp redefinition will intensify. Psychedelics remain prohibited. Harm reduction is a genuine bright spot and runs counter to enclosure (the overdose prevention center is publicly sanctioned and settlement-funded). Net: a small market that stays hard-capped at 24 retailers, but the residency repeal and voided rounds lifted the licensing freeze that had sealed entry, moving the state from heavily enclosed toward partly open, held back from fully open only by the cap. Score: 3/5. (Score revised from 4/5 to 3/5 on July 18, 2026, after the June 2026 residency-requirement repeal (H 8544 / S 3313) lifted the licensing freeze and the CCC began restarting the capped licensing round; an earlier version scored 4/5. Sources: Rhode Island Current and The Marijuana Herald, June 2026.)

What to watch next

Implementation of the June 2026 repeal of the residency requirement (H 8544 / S 3313): the CCC was directed to restart licensing within about 60 days after voiding the prior rounds and refunding fees; the appeal of the residency injunction is now moot. Source: https://rhodeislandcurrent.com/2026/04/14/cannabis-control-commission-appeals-ruling-halting-license-rollout-after-closed-door-meeting/
March 2026 sunset of the overdose prevention center pilot authorization; watch for reauthorization. Source: https://thepublicsradio.org/health/rhode-island-opens-first-state-sanctioned-overdose-prevention-center-in-the-nation/
November 12, 2026: federal hemp THC redefinition takes effect absent a delay; watch the federal Farm Bill, the Hemp Planting Predictability Act, and the HEMP Act. Source: https://www.cannabisbusinesstimes.com/hemp/news/15823852/s-house-passes-2026-farm-bill-intoxicating-hemp-product-ban-remains
Confirmation of Michelle Reddish as CCC chair and how she handles the restarted licensing after the June 2026 residency repeal. Source: https://www.bostonglobe.com/2026/05/27/metro/ri-cannabis-control-commission-michelle-reddish/
The restarted retail licensing process after the June 2026 repeal voided the earlier application rounds; watch the CCC's new timeline and lottery. Source: https://www.cann.dev/rhode-island-cannabis-retail-licensing-2026/
2026 psilocybin bill status (bill numbers unconfirmed) via the trackers.
The Rhode Island General Assembly convenes in January each year; the 2026 regular session is ongoing as of this brief.

Regulators

Cannabis Control Commission (CCC): independent regulator of adult-use and medical cannabis; administers licensing, the lottery, and hemp-intoxicant recommendations. https://ccc.ri.gov/
The Cannabis Office (within the CCC structure): day-to-day cannabis administration. https://ccc.ri.gov/Cannabis_Office
Rhode Island Department of Business Regulation, Office of Cannabis Regulation: predecessor/related regulatory role for medical program rules. https://dbr.ri.gov/office-cannabis-regulation
Rhode Island Department of Health (RIDOH): regulates the overdose prevention center and public-health harm reduction; would write psilocybin rules if FDA reschedules.
Rhode Island Division of Taxation: administers the adult-use cannabis tax. https://tax.ri.gov/tax-sections/sales-excise-taxes/adult-use-cannabis-tax

Federal exposure (2026)

Rhode Island sits at the intersection of nearly every federal lever now in play, and on net the federal posture squeezes the same small actors the state's own caps already squeeze.

Rescheduling and 280E. Cannabis remains Schedule I by default. The DOJ/DEA order signed April 22, 2026 and effective April 28, 2026 (91 FR 22714) moved only FDA-approved cannabis drugs and state-licensed medical cannabis to Schedule III, leaving adult-use (recreational) cannabis in Schedule I. The practical Rhode Island effect is split. The medical program, which is folded into the same Cannabis Control Commission regime, gains real relief, because Schedule III ends the Section 280E tax penalty for that medical category, restoring ordinary business deductions and improving margins for medical activity. Adult-use operators, which is the bulk of the Rhode Island market by sales, get nothing: they stay in Schedule I, keep paying 280E, and remain locked out of interstate commerce and normal banking. Schedule III does not legalize cannabis, does not authorize interstate commerce, and does not reach state recreational businesses, so the seven to nine Rhode Island adult-use retailers carry the full federal tax and banking burden while their medical-side activity is partly relieved. The broader DEA rescheduling hearing opened June 29, 2026 and may slip to 2027, so any wider change is not imminent.

The November 12, 2026 hemp cliff. The FY2026 agriculture appropriations rider (Sec. 781, Rep. Andy Harris R-MD) narrows the federal definition of hemp to a total-THC standard, about 0.4 mg THC per container, recriminalizing roughly 90 to 95 percent of intoxicating hemp products effective November 12, 2026. The H.R.7010 delay was not enacted and the 2026 Farm Bill (H.R.7567) keeps the ban. Rhode Island is already among the most restrictive states here: it caps hemp consumables at 1 mg total THC per serving and 5 mg per package, paused new hemp retailer licenses, and in March 2026 its regulators backed pushing THC beverages out of bars, restaurants, liquor stores, and convenience stores and into the licensed cannabis channel only. The practical effect is therefore reinforcement more than disruption. The federal cliff does to the national off-channel market what Rhode Island has been doing to its own in-state off-channel market, so the state's direction of travel and the federal change point the same way. The losers are the same: convenience stores, liquor retailers, and independent hemp-beverage sellers, who lose the low-THC products that survived under state caps and now fall below the federal total-THC line as well.

Banking. SAFER Banking remains stalled in Congress, so Rhode Island's cannabis operators stay cash-heavy, underbanked, and cut off from normal lending, which compounds the 280E penalty above and raises the capital bar for any new entrant. The 2026 residency story began in the courts but was ultimately resolved by legislation: the dormant Commerce Clause challenge to Rhode Island's 51 percent residency requirement produced an April 8, 2026 federal preliminary injunction (Judge Melissa DuBose) that froze the entire planned expansion to the remaining 24-license cohort, then in June 2026 the General Assembly repealed the residency requirement (H 8544 / S 3313), voided the prior rounds, refunded fees, and directed the CCC to restart licensing within about 60 days, mooting the case. The months of freeze still shaped the capital picture: the delay plus stalled federal banking relief left well-capitalized incumbents and out-of-state capital best positioned as the capped market reopens.

Psychedelics. Psilocybin, MDMA, and ibogaine all remain Schedule I federally. The April 18, 2026 executive order, Accelerating Medical Treatments for Serious Mental Illness [https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/] plus FDA priority vouchers fast-track FDA review, but no psychedelic is approved yet. Rhode Island's recurring Potter (House) and Kallman (Senate) psilocybin decriminalization bill has never been enacted, and by its own design it defers a therapeutic cultivation, distribution, and prescription framework until the FDA reschedules psilocybin. So the route for Rhode Island runs through Washington: the state has tied its therapeutic pathway to federal action, and until FDA approval arrives the bill stays decriminalization-only at most, and in practice has not become law. (2026 bill numbers unconfirmed; see the Psychedelics section and trackers.)

Harm reduction. This is where Rhode Island is most exposed and most distinctive. The April 24, 2026 SAMHSA guidance bars federal funds for fentanyl test strips, clean syringes, and sterile water, while still supporting naloxone. Rhode Island runs unusually strong programs (syringe services, naloxone, fentanyl test strips decriminalized since 2018) and operates the nation's first state-sanctioned overdose prevention center (OPC) in Providence, so the SAMHSA cuts hit core Rhode Island tools directly: test strips and syringe-service supplies that drew federal support now have to be paid for some other way, which for the OPC has meant opioid-settlement dollars rather than federal grants. The OPC also faces federal legal limbo independent of funding. Supervised consumption sites are exposed under the federal "crack house statute" (21 U.S.C. 856) of the Controlled Substances Act, the same provision at issue in the long-running Philadelphia Safehouse litigation, and DOJ has historically treated such sites as an enforcement-discretion question evaluated district by district rather than blessing them. Rhode Island's site has operated without federal intervention so far, but it runs on state authorization and settlement money inside a federal prohibition that could be enforced at any time, so its legal footing is sanctioned by the state and merely tolerated, not protected, by Washington. Source: https://drugpolicy.org/wp-content/uploads/2024/04/DPA-OPC-Legal-Risk-Analysis-Updated-December-2024.pdf and https://whyy.org/articles/philadelphia-safehouse-supervised-consumption-injection-site-overdose-prevention/ and https://www.npr.org/2024/12/11/nx-s1-5217792/rhode-island-opens-nations-first-state-sanctioned-overdose-prevention-center

Patient access and rights

This section covers what Rhode Island law does and does not protect for a medical cannabis patient: use inside a hospital, and the broader rights that follow a patient into work, housing, parenting, an organ transplant list, and school. It is information, not legal advice, and it reflects the law as of July 2026. Each point links to the primary statute.

Hospital access (Ryan's Law): Rhode Island has no hospital-access law. No statute requires a hospital, nursing home, or hospice to let a qualifying patient use medical cannabis on site, so whether a facility allows it is left to that facility's own policy, and many refuse. Seven states have now enacted a Ryan's Law protection (California in 2021, and Colorado, Delaware, Louisiana, Oregon, Virginia, and Washington in 2026), and Pennsylvania has a bill pending; Rhode Island is not among them. The absence is the finding: a Rhode Island patient has no enforceable right to use their medicine in a hospital today.

Broader protections: Rhode Island protects a cardholder in five of the six areas, with parental and custody rights the exception. A single statute, R.I. General Laws Section 21-28.6-4, bars discrimination in employment (subsection (e)), in housing and school enrollment (subsection (d)), and provides that for the purposes of medical care, including organ transplants, authorized use is treated as the equivalent of any other prescribed medication (subsection (s)). A review of Section 21-28.6-4 found no dedicated protection for custody or visitation; that gap is the finding. A Rhode Island patient cannot be denied a transplant listing solely for lawful medical cannabis use.

Out-of-state patients: Rhode Island recognizes an out-of-state medical card for possession only; a visitor may possess, but the recognition does not extend to purchasing at a Rhode Island dispensary.

The federal picture: the April 2026 federal move of state-licensed medical cannabis to Schedule III did not change any of this. Schedule III does not make dispensary cannabis a lawful prescription medicine and does not create any hospital-use right; only state law can force hospital access, and Rhode Island has not enacted a Ryan's Law. The broader protections above are a creature of Rhode Island law, not federal law.

Sources: Rhode Island patient protections, R.I. General Laws Section 21-28.6-4.

Analysis: the enclosure read in depth

Who is fenced out. Rhode Island runs one of the smallest hard-capped adult-use markets in the country: 24 retail establishments maximum, across six zones, four per zone, and in practice only about seven to nine retailers are actually operating, most of them converted medical compassion centers earning some of the highest per-store revenue in the nation. Everyone else is on the outside of that fence. Nearly 100 applicants, including the dedicated social-equity and worker-cooperative tiers, were frozen in litigation limbo for months until the June 2026 repeal of the residency requirement (H 8544 / S 3313) voided the prior rounds, refunded fees, and directed the CCC to restart licensing, though the market stays capped at 24 retailers. New hemp retailers are paused and being funneled into the licensed cannabis channel, which fences out convenience stores, liquor shops, and independent beverage sellers. Psychedelic actors are fenced out entirely by continued prohibition. The structural pattern is a tiny, capped, incumbent-favoring market with an equity layer that cannot enter.

Who consolidates. The seven to nine incumbents consolidate by default. Months of frozen expansion extended their exclusive hold on the highest per-store revenue in the country. The June 2026 repeal of the residency rule (H 8544 / S 3313) adds a second consolidation vector: with the in-state ownership fence gone but the market still capped at 24 retailers, larger and out-of-state capital can now compete for the capped slots, which favors well-financed multistate operators over local and equity applicants who lack comparable capital, especially with SAFER Banking stalled and 280E still biting adult-use. Both phases consolidate value upward: the delay protected incumbents, and the liberalized ownership rule rewards big capital within a still-capped market.

State plus federal interaction. The state caps (24 licenses, residency rule, hemp channeling) and the federal levers (Schedule I for adult-use, 280E, stalled SAFER Banking, the November 12 hemp cliff, the dormant Commerce Clause injunction) pull in the same direction: they raise the capital and compliance bar and fence out small and new actors. The clearest fusion is the residency dispute, where a federal constitutional doctrine froze a state expansion until the legislature repealed the requirement in June 2026, and the hemp cliff, where the federal total-THC standard mirrors and hardens Rhode Island's own restrictive channeling. Medical cannabis is the one place federal action loosens a fence (Schedule III ends 280E for that category), but that relief flows to existing licensed operators, not to new entrants.

Where commons counter-moves are present. The genuine counter-move is harm reduction. Rhode Island's first-in-the-nation, state-sanctioned overdose prevention center, its settlement-funded syringe and naloxone programs, and its 2018 fentanyl-test-strip decriminalization are public-interest, access-expanding moves that run against enclosure. They are now directly exposed to the April 2026 SAMHSA defunding of test strips and syringe supplies and to the unresolved federal "crack house statute" risk over the OPC, so the commons leadership exists but is under federal pressure from both funding and enforcement directions.

What to watch. Implementation of the June 2026 residency repeal (how quickly the CCC restarts and runs the capped licensing round after voiding the prior rounds and refunding fees); the OPC pilot reauthorization past its March 2026 sunset and how the program backfills the SAMHSA cuts; the November 12, 2026 hemp cliff and any last-minute federal delay; and the DEA rescheduling hearing timeline (June 29, 2026, possibly slipping to 2027) that would govern any broader adult-use relief.

Why 3/5. The market is hard-capped and tiny, incumbents are entrenched and richly profitable, hemp is being channeled to incumbents, and psychedelics are closed, all of which is classic enclosure, and the federal levers (Schedule I adult-use, 280E, stalled banking, the hemp cliff) reinforce it. The score moved down from 4 to 3 because the main basis for the 4, a licensing freeze that had sealed the capped market to any new entrant, is gone: the June 2026 repeal of the 51 percent residency requirement (H 8544 / S 3313) voided the prior rounds and directed the CCC to restart licensing, so entry is reopening rather than frozen shut, and the state has moved from heavily enclosed toward partly open. Rhode Island also shows the strongest harm-reduction commons posture in the country (the first state-sanctioned OPC, broad syringe and naloxone access, early test-strip decriminalization), another pull away from a top score. It does not soften below 3 because the 24-retailer cap remains, the restart favors better-capitalized and out-of-state applicants over local and equity entrants, and the hemp and psychedelic channels stay fenced. A market that was capped and permanently closed to new entrants with no countervailing commons leadership would score 5; a fully open market would score lower than 3. Rhode Island now sits at partly open: reopening but still capped.

Active legislation (2026)

This list is not exhaustive. For the full and current set of bills and live status, use LegiScan (https://legiscan.com/RI), the Rhode Island General Assembly site (https://www.rilegislature.gov/).

Beyond the live tracker

These measures are not in the live bill list below: some are not bills (executive orders, rules, referendums, or budgets), and some are proposals or prior-session measures the live tracker does not currently carry.

Psilocybin decriminalization bill (2026 number unconfirmed; historically H 7047) Decriminalize personal psilocybin cultivation/possession up to 1 oz; FDA-contingent therapeutic rulemaking (Recurring; prior House passage and 12-2 committee advance; 2026 final status unconfirmed)
Psilocybin Senate companion (2026 number unconfirmed) Senate version of psilocybin decriminalization (Prior committee hearing; 2026 status unconfirmed)
Hemp THC beverage rules (regulatory, not a bill) CCC dosage/packaging/labeling/licensing recommendations due March 1, 2026; ban on THC drinks in bars/restaurants outside licensed channel (Recommendations delivered March 2026)
Overdose prevention center reauthorization (bill number unconfirmed) Extend authorization beyond March 2026 sunset (Watch item; specific 2026 bill unconfirmed)

Bill	Title/Topic	Chamber	Status	Sponsor(s)
Psilocybin decriminalization bill (2026 number unconfirmed; historically H 7047)	Decriminalize personal psilocybin cultivation/possession up to 1 oz; FDA-contingent therapeutic rulemaking	House	Recurring; prior House passage and 12-2 committee advance; 2026 final status unconfirmed	Rep. Brandon Potter (D)
Psilocybin Senate companion (2026 number unconfirmed)	Senate version of psilocybin decriminalization	Senate	Prior committee hearing; 2026 status unconfirmed	Sen. Meghan Kallman (D)
H 6270 (2025)	Push hemp-derived delta-9 THC beverages/powders into licensed cannabis channel only	House	2025 session bill; informs 2026 regulatory action	Sponsor unconfirmed
Hemp THC beverage rules (regulatory, not a bill)	CCC dosage/packaging/labeling/licensing recommendations due March 1, 2026; ban on THC drinks in bars/restaurants outside licensed channel	n/a (CCC)	Recommendations delivered March 2026	Cannabis Control Commission
Overdose prevention center reauthorization (bill number unconfirmed)	Extend authorization beyond March 2026 sunset	Both	Watch item; specific 2026 bill unconfirmed	Unconfirmed

Note: I deliberately did not invent bill numbers or sponsor names where I could not confirm them; entries marked unconfirmed should be verified against the trackers above.

Support this work

This work is free and reader-funded. No paywalls, no ads. This brief is independent and fully sourced, and reader contributions are what keep the 50-state coverage current and answerable to readers, not advertisers or owners.

If it helped you, please chip in $5 to keep it going. Recurring support helps most; about $25 funds a full refresh of a state brief like this one.

Contribute $5 on Ko-fi Become a member

← Back to all 50 states and federal briefs

A planning snapshot for 2026, not legal advice. Policy moves quickly; confirm any single detail against the cited sources before acting on it. Sponsor names are given where confirmable and marked unconfirmed otherwise.

About the author. Jessica Mantonya is the founder of Drug Policy Watch and Hold in Common. She also advises operators, advocates, and funders on regulatory strategy and anti-enclosure positioning. Work with her →